Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization.

by Nihar R Desai, Christopher G Rowan, Paula J Alvarez, Jeanene Fogli, Robert D Toto
Published 2020-01-01

Alport Syndrome Classification and Management

by Bradley A. Warady, Rajiv Agarwal, Sripal Bangalore, Arlene Chapman, Adeera Levin, Peter Stenvinkel, Robert D. Toto, Glenn M. Chertow
Published 2020-09-01

Sepsis-Associated Acute Kidney Disease and Long-term Kidney OutcomesPlain-Language Summary

by Alexander H. Flannery, Xilong Li, Natalie L. Delozier, Robert D. Toto, Orson W. Moe, Jerry Yee, Javier A. Neyra
Published 2021-07-01

Serum IL-17 levels are higher in critically ill patients with AKI and associated with worse outcomes

by Jason A. Collett, Victor Ortiz-Soriano, Xilong Li, Alexander H. Flannery, Robert D. Toto, Orson W. Moe, David P. Basile, Javier A. Neyra
Published 2022-04-01

Serum renin and major adverse kidney events in critically ill patients: a multicenter prospective study

by Alexander H. Flannery, Victor Ortiz-Soriano, Xilong Li, Fabiola G. Gianella, Robert D. Toto, Orson W. Moe, Prasad Devarajan, Stuart L. Goldstein, Javier A. Neyra
Published 2021-08-01

Kidney Tubular Damage and Functional Biomarkers in Acute Kidney Injury Following Cardiac Surgery

by Javier A. Neyra, Ming-Chang Hu, Abu Minhajuddin, Geoffrey E. Nelson, Syed A. Ahsan, Robert D. Toto, Michael E. Jessen, Orson W. Moe, Amanda A. Fox
Published 2019-08-01

Effects of Dapagliflozin in Patients with Membranous Nephropathy

by Glenn M. Chertow, Hiddo Lambers Heerspink, Patrick B. Mark, Jamie P. Dwyer, Michal Nowicki, David C. Wheeler, Ricardo Correa-Rotter, Peter Rossing, Robert D. Toto, Anna Maria Langkilde, Niels Jongs
Published 2024-06-01

Serum Magnesium Levels and Cardiovascular Outcomes in Systolic Blood Pressure Intervention Trial ParticipantsPlain-Language Summary

by Silvia Ferrè, Yu-Lun Liu, Joshua W. Lambert, Ronit Katz, Fabiola G. Gianella, David A. Drew, Michael G. Shlipak, Orson W. Moe, Joachim H. Ix, Robert D. Toto, Javier A. Neyra
Published 2023-06-01

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial

by Glenn M. Chertow, Ricardo Correa‐Rotter, Priya Vart, Niels Jongs, John J. V. McMurray, Peter Rossing, Anna Maria Langkilde, C. David Sjöström, Robert D. Toto, David C. Wheeler, Hiddo J. L. Heerspink
Published 2023-05-01

The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists

by Michele Provenzano, Niels Jongs, Priya Vart, Bergur V. Stefánsson, Glenn M. Chertow, Anna Maria Langkilde, John J.V. McMurray, Ricardo Correa-Rotter, Peter Rossing, C. David Sjöström, Robert D. Toto, David C. Wheeler, Hiddo J.L. Heerspink
Published 2022-03-01

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placeb...

by Julio Rosenstock, Vlado Perkovic, John H. Alexander, Mark E. Cooper, Nikolaus Marx, Michael J. Pencina, Robert D. Toto, Christoph Wanner, Bernard Zinman, David Baanstra, Egon Pfarr, Michaela Mattheus, Uli C. Broedl, Hans-Juergen Woerle, Jyothis T. George, Maximilian von Eynatten, Darren K. McGuire, CARMELINA® investigators
Published 2018-03-01

Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx

by Michael Crompton, Joanne K. Ferguson, Raina D. Ramnath, Karen L. Onions, Anna S. Ogier, Monica Gamez, Colin J. Down, Laura Skinner, Kitty H. Wong, Lauren K. Dixon, Judit Sutak, Steven J. Harper, Paola Pontrelli, Loreto Gesualdo, Hiddo L. Heerspink, Robert D. Toto, Gavin I. Welsh, Rebecca R. Foster, Simon C. Satchell, Matthew J. Butler
Published 2023-03-01